SAN FRANCISCO, Nov. 13, 2014 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension of injectable drugs, today announced the receipt of a grant from the National Science Foundation (NSF). The grant will support further development of the company's hydrogel platform. The Phase II grant, Award Number IIP-1429972 provides ProLynx with a total of nearly $750,000 of research funding over two years.
ProLynx's hydrogel-drug conjugates enable ultra-long drug release and thus less frequent administration. The hydrogel and drug are chemically connected by proprietary self-cleaving linkers having half-lives of a few days to a few months. The hydrogels are designed to adjustably control the release of a drug over a wide time-range, followed by the pre-programmed degradation and elimination of the hydrogel.
"Our microsphere hydrogel technology offers a unique platform for the sustained release of proteins, peptides and small molecules," said Daniel V. Santi, M.D., Ph.D., ProLynx's founder and president. "Most competing technologies cannot support monthly administration, nor can they be applied to proteins and peptides. This new funding will help support our expansion of the platform as well as preclinical research on specific peptide-hydrogel conjugates in our pipeline."
About ProLynx LLC
ProLynx LLC is a privately held biotechnology company developing proprietary drug delivery systems (DDS) for half-life extension of proteins, peptides and small molecules. The company is seeking to apply its DDS to extend half-lives of drugs and drug candidates of pharmaceutical and biotechnology companies. ProLynx is also seeking to out-license the long lasting drug conjugates in its pre-clinical product portfolio. The company is located in San Francisco, CA. Further information about the company and its capabilities may be found online at http://www.prolynxllc.com.
CONTACT: Peg Horn 415-552-5306 email@example.com